| Symbol | KPHMW |
|---|---|
| Name | KIORA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | - |
| Address | 92024 United States CA 169 Saxony Rd Suite 212 |
| Telephone | (858) 224-9600 |
| Fax | — |
| — | |
| Website | https://kiorapharma.com/ |
| Incorporation | US |
| Incorporated On | 2004 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | EisnerAmper LLP; |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001372514 |
| Description | Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Thea Open Innovation for the development KIO-301. Additional info from NASDAQ: Additional info from OTC: |
Pink Limited symbol attribute type Security_Name was changed. Previous value: KIORA PHARM WT 7/27. New value: KIORA PHARM WTS 9/27/27.
Read moreKiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Read morePink Current symbol attribute type Security_Name was changed. Previous value: -. New value: KIORA PHARM WT 7/27.
Read moreOTCQX U.S. Premier symbol attribute type Security_Name was changed. Previous value: CONSUMERS BANCORP INC. New value: KIORA PHARM WT 7/27.
Read moreKiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Read more